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Learning Objectives 
 To recognise AC as a rare but important cause of sudden cardiac death and heart 
failure. 
 To raise awareness of the broader phenotype of classical arrhythmogenic right 
ventricular cardiomyopathy that includes left ventricular predominance and 
arrhythmogenic dilated cardiomyopathy phenotypes. 
 To understand the clinical features of AC and the clinical approach to diagnosis.  




Phenotype is defined as a set of observable characteristics of an individual resulting from 
the interaction of their genotype with the environment. It differs from “disease” in that it 
does not reflect the mechanism by which it is produced. In 1982, the term arrhythmogenic 
right ventricular dysplasia (ARVD) was first used to describe a clinical phenotype 
characterised by ventricular arrhythmias of left bundle branch block configuration 
accompanied by right ventricular dilatation, wall motion abnormalities and fibrofatty 
replacement of the myocardium 1. Arrhythmogenic right ventricular cardiomyopathy (ARVC) 
became the preferred descriptor when subsequent histopathological analysis revealed that 
myocyte atrophy as a consequence of progressive cell death occurred after birth 2 3. Initial 
clinical diagnostic criteria for ARVC were based upon descriptions of patients with advanced 
disease 4, but discovery of its genetic basis, and the phenotyping of large patient cohorts 
including relatives, revealed a broader disease spectrum in which right and left ventricles 
can be involved 5. The disease paradigm has expanded further with the recognition of new 
disease genes causing similar phenotypes. Hence, terms such as left dominant 
arrhythmogenic cardiomyopathy, arrhythmic dilated cardiomyopathy or simply 
arrhythmogenic cardiomyopathy (AC) are increasingly used to describe the clinical 
phenotype observed in a family of disorders in which frequent ventricular arrhythmia and 
dysfunction of one or both ventricles are the defining features. In this article, we review this 
emerging concept with a focus on the genetics, and clinical presentation of different forms 
of AC and a diagnostic approach based on recognition of particular clinical traits (Figure 1). 
 
PHENOTYPES ENCOMPASSED BY THE TERM ARRHYTHMOGENIC CARDIOMYOPATHY 
(1) Arrhythmogenic right ventricular cardiomyopathy (ARVC) 
Since the 1980s, ARVC has been defined as a progressive primary heart muscle disorder 
characterised by replacement of cardiomyocytes with fat and fibrosis underlying structural 
and functional abnormalities of the right ventricle (RV). The diagnosis of ARVC is based on 
consensus recommendations, originally proposed in 1994 and later revised in 2010 4 6. They 
are relatively complex, compared to other cardiomyopathies (e.g. hypertrophic 
cardiomyopathy), and rely on integration of right ventricular morphology and function 
(assessed by echocardiography, angiography and/or cardiac magnetic resonance imaging), 
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histopathological analysis of endomyocardial biopsy, electrocardiography (ECG), arrhythmia, 
family history and molecular genetic analysis (Table). Quantitative parameters based on 
comparison with normal data are included in the criteria. 
(2) Left Dominant Arrhythmogenic Cardiomyopathy 
By definition ARVC is a right ventricular disease, but detailed phenotypic characterization of 
patients and family members has revealed that the left ventricle (LV) is frequently involved. 
Three main patterns of cardiac involvement are observed: 1) predominant right ventricular 
disease, with minor or absent left ventricular involvement; 2) biventricular disease, when 
both ventricles are affected; and 3) left dominant disease that is characterized by mild or 
absent right ventricular involvement5 7. The terminology used to describe this spectrum is 
poorly defined and at times confusing as it overlaps with current concepts of dilated 
cardiomyopathy8.  
(3) Arrhythmogenic Dilated Cardiomyopathy (ADC) 
In a recent registry study, arrhythmogenic dilated cardiomyopathy (DCM) was defined as a 
DCM phenotype with 1 or more of the following: (1) unexplained syncope (likely due to 
ventricular tachyarrhythmia); (2) rapid non-sustained ventricular tachycardia defined as ≥5 
consecutive ventricular beats lasting <30 seconds, with a rate ≥150/min on 24‐hour Holter 
monitoring; or ≥1000 premature ventricular contractions in, or ≥50 couplets, in 24 hours9. 
By these criteria, one‐third of DCM patients had an arrhythmogenic phenotype that was 
associated with an increased risk of arrhythmia during follow‐up. A family history of 
ventricular arrhythmias predicted a poor prognosis and an increased risk of sudden cardiac 
death (SCD). 
GENETICS AND PHENOTYPE CORRELATION 
Key to discovery of the genetic basis of ARVC was its association with palmoplantar 
keratoderma and woolly hair in Naxos Disease, which is inherited as an autosomal recessive 
trait with full penetrance by adolescence10. A homozygous two-nucleotide deletion in the 
gene encoding plakoglobin (JUP) was identified11. Furthermore, a homozygous recessive 
mutation in the gene encoding desmoplakin (DSP) was identified in people with a similar 
cardiocutaneous phenotype (Carvajal syndrome) associated with highly arrhythmic DCM12. 
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Following identification of desmosomal mutations in recessive disease, other mutations in 
genes encoding the five desmosomal proteins including plakophilin-2 (PKP2), desmoglein-2 
(DSG2) and desmocollin-2 (DSC2), DSP and JUP were identified in cases of autosomal 
dominant disease13-19. PKP-2 mutations represent around 35%–40% of total ARVC cases20, 
followed by mutations in DSP, DSG2 and DSC2 (about 15-20%)21.  Mutations in JUP are very 
rare and account for less than 5% and are often absent in many ARVC cohorts22. 
 Desmosomal protein gene mutations became a defining feature of ARVC and were 
included in consensus task force criteria for its diagnosis6. However, this purist concept has 
become difficult to sustain with the identification of mutations in non-desmosomal genes in 
patients fulfilling current diagnostic criteria for ARVC 23. A number of non-genetic disorders 
also mimic the disease, notably myocarditis. Several genes encoding non-desmosomal 
proteins including desmin (DES), transmembrane protein 43 (TMEM43), transforming 
growth factor β-3 (TGFB3), lamin A/C (LMNA), titin (TTN), phospholamban (PLN), and filamin 
C (FLNC) have been implicated in phenotypes within the spectrum of arrhythmogenic 
cardiomyopathy. 
 DES mutations lead to heterogeneous myopathies ranging from skeletal muscle 
disease to isolated cardiomyopathy24. So far, less than 10 pathogenic variants linked to AC 
have been identified in DES gene.  
 A mutation in the gene encoding TMEM43 was identified in a founder population in 
Newfoundland, Canada25. Five mutations have been described so far resulting in a clinical 
phenotype that presents significantly earlier in males, shows biventricular involvement and 
is characterized by a high incidence of premature SCD and severe heart failure in survivors26. 
 Genetic alterations in LMNA are associated with a heterogeneous group of disorders 
commonly named ‘laminopathies,’ including dilated cardiomyopathy associated with a high 
incidence of conduction disease and ventricular arrhythmia. Male sex is associated with 
higher incidence of malignant ventricular arrhythmias and heart failure. In 2012, a genetic 
study in a cohort of 108 ARVC patients identified mutations in the LMNA gene in 4% of 
affected individuals27. The clinical phenotype was associated with mild systolic LV 
dysfunction, atrial arrhythmias and conduction system disease.  
 Mutations in TTN and PLN are commonly associated with DCM. Eight missense 
mutations in the TTN gene have been reported in ARVC patients 28 and a founder PLN 
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mutation has been linked to Dutch families with both DCM and ARVC phenotypes 29.   
 Mutations in the FLNC gene have been associated with myofibrillar myopathies. 
Genetic screening of patients with inherited cardiomyopathies and sudden death has been 
identified FLNC mutations in patients with an overlapping phenotype of dilated and left-
dominant arrhythmogenic cardiomyopathies. The phenotype is characterised by variable 
degrees of LV dilation and systolic dysfunction, prominent subepicardial and/or 
intramyocardial fibrosis of the LV, frequent ventricular arrhythmias, and sudden cardiac 
death30. 
 Recent studies have suggested that mutations in SCN5A may account for a small 
portion of the ARVC phenotype cohorts31. This is consistent with multiple studies which 
have demonstrated that desmosomal proteins are associated with altered kinetics of the 
sodium current in cardiomyocytes32, a manifestation which precedes structural 
abnormalities, as seen in a DSG2 mouse model33. Finally, mutations in the genes encoding 
for cadherin 2 and αT-catenin have been very rarely identified among patients with AC34 35.  
 
A CLINICAL APPROACH TO THE DIAGNOSIS OF AC 
Distinction between the various AC phenotypes is more than a simple matter of nosology as 
emerging evidence suggests that aetiology impacts substantially on the natural history and, 
by implication, treatment of individual patients. Current consensus recommendations (2010 
Task Force Criteria) for diagnosis of ARVC focus predominantly on classical signs of right 
ventricular disease coupled with histology and genotype, whereas DCM is a much simpler 
concept defined only by left ventricular size and function with no reference to ECG, genetics 
or cardiac histology. A recent European Society of Cardiology position statement has 
recognised that there are scenarios such as preclinical or early disease in relatives of people 
with genetic forms of DCM and ARVC that do not fulfil conventional diagnostic criteria or fall 
into an overlap where they can be classified into different disease groups8. A new category 
of hypokinetic non-dilated cardiomyopathy has been proposed to account for some of these, 
but this also fails to capture the not infrequent scenario of isolated LV scarring in the 
absence of wall motion abnormality (Figure 2).  
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While consensus still needs to be reached on an integrated classification of AC, there are 
some common principles that can orient clinical diagnostic and management pathways. AC 
should be considered in the presence of the following: 
a. Structural abnormalities of the myocardium including regional or global 
systolic dysfunction or myocardial scar in either ventricle, unexplained by 
ischaemic heart disease or an acute inflammatory trigger by an identifiable 
cause such as viral infection or exposure to a toxic agent. 
b. Frequent ventricular ectopy, sustained or non-sustained ventricular 
tachycardia, or unexplained cardiac arrest. 
There are a number of features that can suggest specific aetiologies in people with systolic 
dysfunction on either or both ventricles associated with frequent ventricular arrhythmia. 
(i) Family History 
Genetic disease is reported in up to 60% of reported AC cases.  Detailed family history and 
familial evaluation are important aids to diagnosis and identify asymptomatic individuals at 
risk of disease complications. A family history of AC, ventricular arrhythmia, and young 
sudden deaths are important pointers to a diagnosis. The presence of atrioventricular block 
or atrial fibrillation in family members can indicate a specific genetic defect (e.g. LMNA, 
SCN5A) particularly if co-existing with young sudden cardiac deaths. Implantable 
cardioverter defibrillator (ICD) implants or heart failure in relatives should also be noted.  A 
clinical episode of acute myocarditis might be significant in an individual suspected of having 
AC as emergence of cardiac symptoms with such episodes has been reported in JUP 
homozygotes with Naxos syndrome and in dominant AC families 36-38. This is further 
supported by experimental evidence in a DSG2 mouse model where marked inflammation 
preceded the development of the overt fibrosis39. 
(ii) Physical Examination 
Cardiovascular examination is important in the assessment of all patients, but the frequently  
subtle pathology of AC means that it may be non-contributory except in advanced disease 
with ventricular dilatation and systolic impairment 10 40 41  On the other hand, examination 
of the skin and hair in the affected patients and their family members can be helpful. Woolly 
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hair and palmo-plantar hyperkeratosis is typical of JUP homozygotes and is also observed in 
heterozygous carriers of mutations in DSP42. Additionally, homozygous DSC2 traits associate 
with late onset AC with palmoplantar keratosis43.  
 Several skeletal myopathies are associated with an arrhythmogenic cardiomyopathy 
phenotype. These include proximal muscle weakness that resembles limb-girdle muscular 
dystrophy caused by FLNC mutations44. Desmin mutations are also associated with a variety 
of myopathies, the most common being a distal leg muscle weakness spreading to proximal 




Ventricular arrhythmias are a defining feature of AC and take the form of ventricular 
extrasystoles (VES), non-sustained or sustained ventricular tachycardia (VT) and ventricular 
fibrillation (VF).  They most commonly arise from the right ventricle in typical ARVC (Figure 
3) but left ventricular arrhythmias are seen in the biventricular and left-dominant sub-
phenotypes 46.  
Current taskforce criteria for ARVC suggest that more than 500 VEs in 24h is a minor 
criterion for the disease 6. However, daily variability in the number of VEs is common and 
may result in underdiagnosis47. An association between the total number of VEs per 24h and 
the arrhythmic potential for unstable ventricular arrhythmias has been demonstrated48. VEs 
may also present prior to the formation of structural/functional alterations identifiable with 
conventional imaging49; in ARVC this phenomenon has been attributed to early loss of 
junctional connexin 43 and micro-re-entry 49. 
Depending on the underlying ventricular origin, sustained monomorphic VT may 
have left bundle branch block (LBBB) and superior axis or right bundle branch block (RBBB) 
morphology 50 51. Other morphologies such as LBBB with inferior axis mimicking idiopathic 
right ventricular outflow tract (RVOT) tachycardia also occur52. VF is the predominant 
mechanism underlying sudden cardiac death in AC and is related to active disease 
progression53. Paradoxically, ventricular arrhythmias are often less frequent in patients with 




Precordial T wave inversion (TWI), up to V3, is observed in 4% of healthy women and 1% of 
men but its presence in the anterior precordial leads in the absence of RBBB raises the 
possibility of  classical ARVC where they are present in more than 70% of patients 6. 
Electrophysiological studies show a correlation between the electroanatomic voltage scar 
area in the right ventricle with the extent of TWI in the anterior leads55. In other forms of 
AC, T wave abnormalities can extend to all precordial leads or be confined to the 
inferolateral leads (suggestive of the left dominant form) 56. TWI can precede structural 
abnormalities seen on conventional imaging. 48 55 57.  
 
Depolarization abnormalities 
Myocardial degeneration and fibrosis in AC leads to the formation of slow conducting 
myocardial regions and abnormalities in depolarization on the surface ECG.  The type and 
frequency of depolarization abnormalities is dependent on the sub-phenotype of AC. Typical 
ARVC, where right ventricular disease predominates, is characterized by prolonged terminal 
activation duration (≥55 ms) of the QRS complex in leads V1-V3 and in more severely 
affected cases epsilon waves may form 58 (See Figure 3). Epsilon waves defined as 
reproducible low-amplitude signals after the end of the QRS complex up to the onset of the 
T wave are detected in approximately 20-30% of ARVC cases. They are usually present in the 
anterior precordial leads and can extend to infero-lateral leads59. It is important that they 
are strictly defined as waves separated from QRS complex by an isoelectric line to avoid 
misinterpretation of fragmentation in the final portion of the QRS complex 60. Epsilon waves 
have been associated with significant structural abnormalities of the right ventricle, 
particularly of the right ventricular outflow tract59. Signal averaged ECG is another means of 
detecting delayed  late potentials and it can be positive in all forms of AC as it represent 
fibrosis in either ventricles 61. 
Abnormal depolarization is also demonstrated by three-dimensional electroanatomic 
voltage mapping which can demonstrate low-voltage areas caused by fibrofatty 
replacement of the myocardium62. This technique can be useful in differentiating AC from 
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RVOT tachycardia and may aid in the risk stratification for life threatening arrhythmias63. An 
epicardial mapping approach is sometimes helpful as disease is mostly subepicardial64. 
A relatively new concept in the AC phenotype is the presence of delay in the 
specialised conduction system. In typical ARVC the most common conduction abnormality 
seen is RBBB which usually signifies advanced disease, masking altogether epsilon waves, 
TAD and late potentials on signal-averaged ECG59. A recent study has suggested that first 
degree atrioventricular (AV) block is present in 1 in 4 AC patients and it is an independent 
risk factor for heart failure hospitalizations65. However, within the broad spectrum of AC, AV 
conduction defects are seen especially in patients with DES, LMNA, Titin or FLNC mutations. 
These may range from first to third degree AV block 30 66-68.  
Imaging 
Classification of the structural abnormalities that can occur in different forms of AC is a 
considerable challenge because they are so diverse and may not align with existing disease 
paradigms. Nevertheless, a relatively simple approach to the multimodality assessment of 
cardiac form and function is invaluable in orienting diagnosis and treatment decisions. 
The essential components of the imaging assessment of AC include the following: 
1 Assessment of global and regional function of the left and right ventricle. 
2 Assessment of the presence and distribution of fibrosis and adipose tissue in both 
ventricles. 
3 Exclusion of co-existing cardiac or extra-cardiac pathologies that can result in 
phenocopies. 
In classical ARVC caused by desmosomal mutations, wall motion abnormalities (dyskinesia, 
akinesia or aneurysm formation) are most common in the anterior, lateral, apical and 
postero-diaphragmatic wall of the RV (Figure 4). In advanced disease, the RV apex and 
infero-lateral LV wall may be involved. In left dominant forms of AC, there may only be 
scarring in the posterolateral LV segments, often without wall motion abnormalities (Figure 
2). In both ARVC and left dominant AC, severe dilatation of either ventricle is rare until the 
very late stages of disease. Circumferential scarring is described in mutations causing the 
left dominant forms of the disease such as FLNC and DSP mutations30 69 in contrast to 
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cardiac sarcoidosis where scarring is often in the basal segments of the LV and septum 
which are usually spared in genetic forms of AC 70. Chest imaging showing lymphadenopathy 
or pulmonary infiltrates should prompt consideration of sarcoidosis in the differential 
diagnosis. 
Other important phenocopies not to miss include intra- or extra-cardiac shunts (suggested 
by evidence for right ventricular pressure or volume overload, pulmonary hypertension and 
tricuspid regurgitation) and cardiac displacement associated with thoracic cage 
abnormalities (pectus deformity, kyphoscoliosis) or partial absence of the pericardium.  
 
MANAGEMENT 
Management of AC can be subcategorized into symptom relief and the prevention of 
sudden cardiac death.  
Lifestyle modification 
All patients with AC should be advised to avoid participation in sports at a professional level 
and to pursue recreational exercise cautiously as it has been demonstrated that there is a 
link between exercise intensity and disease development and arrhythmic risk in a number of 
sub-phenotypes 71-73. Reduction in exercise duration and dose has been correlated with 
decrease in ventricular arrhythmias, but not enough to warrant modification of ICD-
indications74. 
Pharmacological management 
Pharmacological management is used to control symptoms caused by ventricular 
arrhythmias or heart failure. However, anti-arrhythmic drugs do not reduce the probability 
of sudden cardiac death and few data exist about their efficacy in different forms of AC.  In 
ARVC, amiodarone alone or in combination with beta blockers appears to be the most 
effective strategy but sotalol is frequently used as a long-term option in young individuals75. 
Evidence about prophylactic use of b-blockers or amiodarone in asymptomatic individuals 
do not exist and so they are not commonly used. 
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The management of right and left heart failure symptoms is based on conventional heat 
failure management strategies but there are no data on the efficacy of angiotensin-
converting-enzyme inhibitors, β-blockers or mineralocorticoid-receptor-antagonists in AC 76.  
Thrombo-embolic risk in patients with AC is uncertain as there is only a single study that 
identifies reporting an annual incidence of 0.5%77. Certain subgroups of patients, such as 
those with LMNA mutations have been demonstrated to have higher thrombo-embolic 
risk78. It is suggested that patients with AC are anticoagulated in the presence of 
documented intra-cavitary thrombus or systemic thromboembolism79. The lack of evidence 
for risk stratification of patients with atrial fibrillation leads to the decision for 
anticoagulation being made on individual basis but use of the CHA2DS2VASc score is 
untested in this population.  
Ablation of arrhythmias 
VT often arises as the consequence of macro-reentry around scars80. Catheter ablation can 
be used to reduce the risk of developing sustained ventricular arrhythmia with reported 
success in up to 60-80%, especially with an epicardial approach81. However, due to the 
progressive nature of the disease, recurrence is frequent and catheter ablation should 
always be combined with optimal pharmacological therapy.  
Heart Transplantation 
Heart transplantation is reserved for those patients with refractory ventricular arrhythmias 
and in patients with intractable heart failure where conventional management is not able to 
provide an acceptable quality of life79.  
Risk stratification and indications for ICD implantation 
One of the primary goals in the management of AC is to identify patients at high risk of SCD 
who may benefit from prophylactic ICD implantation. Neither pharmacologic treatment or 
catheter ablation has been shown to reduce sudden cardiac death risk. The majority of data 
on risk stratification of AC are based on studies of the ARVC phenotype79. Arrhythmic risk in 
this context has been stratified in three categories: high, intermediate and low (Figure 5). 
The intermediate risk group is further subcategorised according to the presence of major 
and minor risk factors. Major risk factors include syncopal episodes unrelated to 
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extracardiac causes or reflex mediated changes in vascular tone and/or heart rate, non-
sustained ventricular tachycardia and moderate left or right ventricular dysfunction. Minor 
risk factors include many features for which prognosis evidence is weak or absent. These 
include proband status, male gender, compound or digenic heterozygosity, extent of TWI in 
the inferior leads or beyond lead V3 from the precordial leads, QRS fragmentation, extent of 
electroanatomic voltage mapping scar, inducible VT/VF and young age48 50 57 63 82-88. ICDs are 
generally indicated for high risk patients and are considered for those with major risk factors 
that belong to the intermediate risk group. Implantation of an ICD in patients that have only 
minor risk factors may be considered but only after a careful discussion of the risks and 
benefits. Finally, ICD implantation is contraindicated in patients without risk factors or in 
healthy mutation carriers79. 
 Left dominant forms of AC are under-represented in most of risk stratification 
studies and data regarding stratification of arrhythmic risk in these patients do not exist.  
Similarly, while patients with the arrhythmogenic forms of dilated cardiomyopathy are 
known to have higher arrhythmic risk than the other DCM patients, there are no clinical 
tools available to quantify this risk and to guide ICD implantation9. Nevertheless, emerging 
data suggest that ICD implantation is reasonable in subtypes of AC associated with mild-
moderate left ventricular dysfunction such as disease caused by Filamin C, LMNA and DES 
mutations. In LMNA and DES related disease there is often a pacing indication as well as a 
high risk of ventricular arrhythmia.  
Follow up 
Study of patients in AC cohorts with long follow up has revealed that disease progression is 
common89. Periodic reassessment of the arrhythmic risk is important as evolution of the 
ECG abnormalities occurs more frequently than structural abnormalities90. In general, 
healthy mutation carriers should also be evaluated, once every one to two years, with 24h 
tape, ECG and standard echocardiogram and whenever new symptoms such as syncope or 
palpitations appear. 
Family screening 
Screening of the first-degree family members is advisable as it identifies other individuals 
with the disease who are potentially at risk for sudden cardiac death. The presence of a 
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pathogenic mutation in the proband permits cascade genetic testing of relatives and the 
exclusion of mutation-negative family members from further follow-up. However, 
physicians should be cautious with interpretation of genetic results within this context and 
only discharge patients when it is certain that a genetic variant is pathogenic and there is no 
possibility of additional pathogenic genetic variants in the family. As the disease usually 
develops from adolescence onwards, clinical screening at yearly to two-yearly intervals 
should be considered from the age of 10-12 years91. 
Summary and conclusions 
AC represents a diverse group of myocardial disorders that can have a more malignant 
arrhythmic course compared to other cardiomyopathies. They are primarily defined by the 
high burden of ventricular arrhythmia and structural abnormalities of varying severity. 







 AC refers to a group of myocardial disorders that have a high burden of ventricular 
arrhythmias and can affect one or both ventricles.  
 In contrast to classical DCM, patients with AC can have a malignant arrhythmic 
course even with mild ventricular dysfunction. 
 Three major sub-phenotypes are classical ARVC, left dominant arrhythmogenic 
cardiomyopathy and arrhythmogenic DCM.  
 AC is familial in about 60% of cases. 
 Diagnostic criteria and management guidance exist for ARVC but further studies are 
required to define other forms of AC 
 ECG abnormalities can precede overt structural manifestations. 
 Symptomatic presentation of ventricular arrhythmias or a history of arrhythmic 
cardiac arrest in an otherwise normal myocardium should raise suspicion of an early 
AC phenotype. 
 Exercise may promote disease progression and ventricular arrhythmia.  












Table 1: Revised task force criteria for the diagnosis of ARVC 
Revised Task Force Criteria for the diagnosis of ARVC 
Features Major Minor 
Arrhythmias •Non-sustained or sustained ventricular tachycardia of 
left bundle-branch block morphology with superior axis 
(negative or indeterminate QRS in leads II, III, and aVF and positive in lead 
aVL). 
•Non-sustained or sustained ventricular tachycardia of RV 
outflow configuration, LBBB-morphology with inferior axis 
(positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown 
axis). 
•> 500 VES /24 hours (Holter)  
Repolarization 
abnormalities 
•Inverted T waves in right precordial leads (V1, V2, and 
V3) or beyond in individuals >14 years of age (in the 
absence of complete RBBB). 
•Inverted T waves in leads V1 and V2 in individuals > 14 
years of age (in the absence of complete RBBB) or in V4, 
V5, orV6 
•Inverted T waves in leads V1, V2, V3 and V4 in individuals 
> 14 years of age in the presence of complete RBBB 
Depolarization 
abnormalities 
•Epsilon waves (reproducible low-amplitude signals between end of 
QRS complex to onset of the T wave) in the right precordial leads 
(V1 to V3). 
 
•Late potentials by SAECG in ≥1 of 3 parameters in the 
absence of a QRS duration of 110 ms on the standard 12-
lead ECG: 
 Filtered QRS duration ≥ 114 ms. 
 Duration of terminal QRS less than 40 mV (low-amplitude signal 
duration) ≥ 38 ms. 
 Root-mean-square voltage of terminal 40 ms ≤ 20 mV. 
•Terminal activation duration of QRS ≥ 55 ms (measured from 
the nadir of the S wave to the end of the QRS, including R’, in V1, V2, or V3) in 
the absence of complete RBBB. 
Structural wall •Regional RV akinesia, dyskinesia, or aneurysm and 1 of •Regional RV akinesia or dyskinesia and 1 of the following 
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motion abnormalities, 
by 2D echo 
the following (end diastole): 
- PLAX RVOT ≥ 32 mm (corrected for body size [PLAX/BSA] ≥19 
mm/m2) 
- PSAX RVOT ≥ 36 mm (corrected for body size [PSAX/BSA] ≥21 
mm/m2) 
- or fractional area change ≤33% 
(end diastole): 
- PLAX RVOT ≥ 29 to <32 mm (corrected for body size [PLAX/BSA] ≥16 
<19 mm/m2) 
- PSAX RVOT ≥ 32 to <36 mm (corrected for body size [PSAX/BSA] ≥18 
to <21 mm/m2) 
- or fractional area change >33% to ≤ 40%  
by CMR •Regional RV akinesia or dyskinesia or dyssynchronous 
RV contraction and 1 of the following: 
- Ratio of RV end-diastolic volume to BSA ≥ 110 mL/ m2 
(male) or ≥ 100 mL/ m2 (female) 
- or RV ejection fraction ≤ 40% 
•Regional RV akinesia or dyskinesia or dyssynchronous RV 
contraction and 1 of the following: 
- Ratio of RV end-diastolic volume to BSA ≥ 100 mL/m2 to 
<110 mL/m2 (male) or ≥ 90 mL/ m2 to <100 mL/m2 (female) 
- or RV ejection fraction >40% to ≤45% 




•Residual myocytes <60% by morphometric analysis (or 
<50% if estimated), with fibrous replacement of the RV 
free wall myocardium in ≥ 1 samples, with or without 
fatty replacement of tissue on endomyocardial biopsy. 
•Residual myocytes 60% to 75% by morphometric analysis 
(or 50% to 65% if estimated), with fibrous replacement of 
the RV free wall myocardium in ≥1 samples, with or 





•ARVC/D confirmed in a first-degree relative who 
meets current Task Force criteria. 
•ARVC/D confirmed pathologically at autopsy or 
surgery in a first degree relative. 
•Identification of a pathogenic* mutation categorized 
as associated or probably associated with ARVC/D in 
•History of ARVC/D in a first-degree relative in whom it is 
not possible or practical to determine whether he meets 
current Task Force criteria. 
•Premature sudden death (<35 years of age) due to 
suspected ARVC/D in a first-degree relative. 
•ARVC/D confirmed pathologically or by current Task Force 
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the patient under evaluation. Criteria in a second degree relative. 
BSA, body surface area; LBBB, left bundle branch block; PLAX, parasternal long axis; PSAX, parasternal short axis; RBBB, right bundle branch block; RV, right ventricular; RVOT, right ventricular 
outflow tract; SAECG, signal averaged ECG. 
* A pathogenic mutation is a DNA alteration associated with ARVC that alters or is expected to alter the encoded protein, is unobserved or rare in a large, non-ARVC, control population, and 
either alters or is predicted to alter the structure or function of the protein or has demonstrated linkage to the disease phenotype in a conclusive pedigree. 
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Figure 1: Schematic representation of the distribution of disease between the two ventricles 
of the currently used nosologic definitions. Arrhythmogenic right ventricular 
cardiomyopathy, most commonly affects the right ventricle or it is biventricular. In left-
dominant arrhythmogenic cardiomyopathy the left ventricle is predominantly affected but 
there are cases with minor right ventricular involvement. Hypokinetic non-dilated 
cardiomyopathy, arrhythmogenic dilated cardiomyopathy and isolated non-ischaemic LV 








Figure 2: Magnetic resonance images from 4 patients with AC. A and B are FLNC mutation 
carriers whereas C and D are DSP mutation carriers.  Late gadolinium enhancement (LGE) 
areas of the myocardium are marked with white arrows. All patients demonstrate 
subepicardial LGE in the inferolateral wall of the left ventricle. At a lesser degree, LGE is 
seen in the midwall of the intraventricular septum. 
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Figure 3: Typical electrocardiographic features are demonstrated from ECG recording of 
patients with AC including T-wave inversions in leadsV1-V3 and beyond (A), prolonged 
terminal activation duration (annotated between the dotted lines) more than 55 ms (B), 
epsilon waves (annotated by black arrows) and (C) typical ventricular tachycardia with left 




Figure 4: Imaging studies of three different AC patients with wall motion abnormalities are 
presented in this figure. Dotted line separates diastole (left) from systole (right). Patient A 
had a normal ECHO study but on cardiac magnetic resonance multiple subtle dyskinetic 
areas (white arrow) are noted in the right ventricular inflow tract. Typical dyskinesia for the 
right ventricular free wall is noted in a 2D-echocardiographic subcostal view in patient B. 
Patient C echocardiographic study demonstrates among others an apical aneurysm (seen 
both in diastole and systole) as seen in this modified four chamber apical view. LA=left 






Figure 5: This diagram demonstrates the approach to the risk stratification of patients with 
AC or their mutation positive family members, based on the International Task Force 
consensus79. Based on the annual arrhythmic event rate of more than 10%, between 1 and 
10% and less than 10% the high, intermediate and low risk groups are defined. * Severe 
right ventricular and/or left ventricular dysfunction is defined as RV fractional area change 
≤17%, or RV ejection fraction≤35%, LV ejection fraction ≤35%. ** Moderate left or right 
ventricular dysfunction is defined as RV fractional area change between 24 and 17% or RV 
ejection fraction between 40 and 36% or LV ejection fraction between 45 and 36%. *** 
Minor risk factors defined in text. ARVC=Arrhythmogenic right ventricular cardiomyopathy; 
ICD=Intracardiac cardioverter defibrillator.  
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